Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 5, 2005, Pages 173-182

  Lee, Dae Y ^a   Kim, Ji Y ^a   Kim, Yu C ^a   Kwon, Jong W ^b   Kim, Won B ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

Pharmacokinetics; Rats; Torasemide

Indexed keywords

SERUM ALBUMIN; TORASEMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; FIRST PASS EFFECT; HEART; HEART OUTPUT; IN VITRO STUDY; LIVER; LUNG; MALE; NONHUMAN; PROTEIN BINDING; RAT; TISSUE HOMOGENATE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIURETICS; DRUG STABILITY; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 22144439386     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.447     Document Type: Article

References (37)

1. Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet 1998; 34: 1-24.
2. Lupinacci L, Puschett JB. An examination of the site and mechanism of action of torasemide in man. J Clin Pharmacol 1988; 28: 441-447.
3. Wittner M, Stefano AD, Wangemann P, Greger R. How do loop diuretics act? Drugs 1991; 41: 1-13.
4. Spahn H, Knauf H, Mutschler E. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur J Clin Pharmacol 1990; 39: 345-348.
5. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991; 41(Suppl. 3): 14-22.
6. Lesne M, Clerckx-Braun F, Duhoux P, van Ypersele de Strihou C. Pharmacokinetic study of torasemide in humans: an over view of its diuretic effect. Int J Clin Pharmacol Ther Toxicol 1982; 20: 382-387.
7. Neugebauer G, Besenfelder E, von Möllendorff E. Pharmacokinetics and metabolism of torasemide in man. Arzneim-Forsch/Drug Res 1988; 38: 164-166.
8. Ghys A, Denef J, de Suray JM, et al. Pharmacological properties of the new potent diuretic torasemide in rats and dogs. Arzneim-Forsch/Drug Res 1985; 35: 1520-1526.
9. Bae SK, Lee DY, Lee AK, et al. Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. J Pharm Sci 2004; 93: 2388-2398.
10. Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant nagase analbuminemic rats. Biopharm Drug Dispos 2003; 24: 27-35.
11. Kim SH, Moon YJ, Ryu C-K, Lee MG. Pharmacokinetics, stability, and blood partition of 7-anilino-5,8-isoquinolinedione, a new isoquinolinedione derivative. Res Commun Mol Pathol Pharmacol 2000; 107: 419-429.
12. Lee MG, Chen M-L, Chiou WL. Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide. Res Commun Chem Pathol Pharmacol 1981; 34: 17-28.
13. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
14. Kim SH, Kim WB, Lee MG. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats. Drug Metab Dispos 1999; 27: 710-716.
15. Litterst CL, Mimnaugh EG, Regan RL, Gram TE. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 1975; 3: 259-265.
16. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
17. Kim YC, Lee MG, Ko S-H, Kim SH. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. J Pharm Pharmacol 2003; 55: 1515-1522.
18. Yoon WH, Yoo JK, Lee JW, Shim CK, Lee MG. Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7, after intravenous and oral administration to rats, rabbits, and dogs. Drug Metab Dispos 1998; 26: 152-163.
19. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
20. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel-Dekker: New York, 1982.
21. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
22. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
23. Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 1980; 69: 90-91.
24. Prandota J, Prutt AW. Furosemide binding to human albumin and plasma of nephrotic syndrome. Clin Pharmacol Ther 1975; 17: 159-166.
25. Shim HJ, Lee MG, Lee MH. Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique. J Clin Pharm Ther 1991; 16: 467-476.
26. Lee SH, Lee MG. Factors influencing the protein binding of azosemide using an equilibrium dialysis technique. Biopharm Drug Dispos 1995; 16: 615-626.
27. Shaw LM, Fields L, Mayock R. Factors influencing theophylline serum protein binging. Clin Pharmacol Ther 1982; 32: 490-496.
28. Gehr TW, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacokinetics of intravenous and oral torasemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 31-38.
29. Brater DC, Rudy DR, Voelker JR, Greene PK, Gehr T, Sica DA. Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency - preliminary evaluation. Cardiovasc Drugs Ther 1993; 7: 69-73.
30. Vargo D, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. The pharmacodynamics of torasemide in patients with congestive heart failure. Clin Pharmacol Ther 1994; 56: 48-54.
31. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
32. Andreasen PB, Vesell ES. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther 1974; 16: 1059-1065.
33. Kim HJ, Kim SH, Kim S-O, et al. Dose-dependent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31378, in rats. Biopharm Drug Dispos 2000; 21: 279-284.
34. Kim SO, Kwak SH, Lee BH, et al. Dose-dependent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31378, in dogs. Biopharm Drug Dispos 2004; 25: 143-148.
35. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
36. Mitruka BM, Rawnsley HM. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans (2nd edn). Masson Publishing USA: New York, 1982.
37. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.